ClinicalTrials.gg
Not yet recruitingNCT04957849NET-OCEANUpdated Jul 12, 2021

Acute Hypertensive Cerebral Hemmorrhage Surgery

An interventional study of The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery and Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach in Hypertensive Intracerebral Hemorrhage, sponsored by Shanghai Changzheng Hospital. Not yet recruiting at 1 site in China. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-12.

Sponsored by Shanghai Changzheng Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Hemorrhage, Hypertensive · China.

Planned enrollment
2nd of 10
1,000 · median 353
Started
2022
with 1 other
No phase
6 of 11
2 open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Shanghai Changzheng Hospital

Among the 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 6 with no phase, and was the 7th registered.

Intracranial Hemorrhage, Hypertensive

23 studies on the registry are indexed under Intracranial Hemorrhage, Hypertensive; 8 are open to participants now.

Browse Intracranial Hemorrhage, Hypertensive studies →

Open to participants now

4 of the 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1 Intracranial Hemorrhage, Hypertensive study recruiting now, none set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China, or all of them as a file.
02

Study summary

The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery: a Multi-center Clinical Trial

Read the detailed description

To evaluate the effect of different surgical approaches on the prognosis of patients with hypertensive intracerebral hemorrhage, hypertensive patients who met the diagnostic criteria of American guidelines for the treatment of adult spontaneous intracerebral hemorrhage (2015) were selected. The time from onset to admission was less than 8 hours. Blood routine examination, liver and kidney function, coagulation system, infectious diseases and other examinations were performed before operation, with emergency surgical indications, They were divided into two groups: transfrontal keyhole approach and transoccipital keyhole approach. Emergency endoscopic hematoma removal was performed. The patients were systematically evaluated and followed up at 1 week, 1 month, 3 months, 6 months and 12 months after operation to observe the improvement of consciousness, GCS score, postoperative rebleeding (appearance, bleeding volume, location, broken into ventricle, etc.), The prognosis was evaluated by ADL score, GCS score, gos score, modified Rankin scale, Mrs scale and ICH Score (GCS, hematoma volume, intraventricular hemorrhage, infratentorial source, patient age, etc.).

03

Conditions studied

  • Hypertensive Intracerebral Hemorrhage

Keywords

  • neuroendoscope
  • trans-occipital approach
  • Acute Hypertensive Cerebral Hemmorrhage
  • Low-drainage Surgery
04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed patients with spontaneous cerebral hemorrhage in the basal ganglia (in line with the diagnostic criteria of the American Adult Spontaneous Cerebral Hemorrhage Treatment Guidelines (2015)).
  2. Head CT showed; hematoma volume ≥ 30ml, intraventricular hemorrhage is not counted as hemorrhage volume.
  3. Time from onset to hospital admission ≤8h.
  4. The age of the patient is 15-75 years old.
  5. Glasgow Coma Score (GCS)> 5 points.
  6. The patient/family knows and signs the form.
  7. Have a clear history of hypertension in the past.

Exclusion criteria

Exclusion Criteria:

  1. Bleeding caused by aneurysm, vascular malformation or tumor stroke.
  2. Combined with a history of head injury or trauma.
  3. There is more blood in the skull.
  4. Past mental disorders or neurological dysfunction.
  5. A history of procoagulant dysfunction or anticoagulant drugs.
  6. Patients with complications such as liver and kidney dysfunction.
  7. Those with poor compliance.
  8. Pregnant patients.
  9. With massive hemorrhage of the ventricle (the area of the hematoma in the CT side is larger than 1/2 of the transverse section), hemorrhage in the third and fourth ventricles with enlarged ventricles.
  10. With late-stage cerebral herniation (bilateral dilated pupils, central respiratory and circulatory failure).
  11. Severe cardiovascular and cerebrovascular diseases: such as myocardial infarction, cerebral infarction, coronary heart disease, myocarditis, malignant arrhythmia, etc.
  12. Participate in other clinical research 3 months before enrollment.
  13. The doctor in charge believes that the study plan cannot be followed.
  14. Those who are or plan to become pregnant or breastfeeding.
  15. Those who are known to be allergic to test drugs or related products.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Trans-frontal keyhole approach

    After general anesthesia, the patient was placed in supine position with head frame fixed. A straight or arc incision was made in the hairline of the affected side. The incision was 3cm beside the midline. The length of the incision was about 4cm and the diameter of the bone window was about 2.5cm. According to the preoperative thin-layer CT scan, the dura mater and part of the cerebral cortex were cut, and the endoport and other hard channels were inserted. The incision reached 2 / 3 of the length of the hematoma along the direction parallel to the long axis of the hematoma, During the operation, mini aneurysms were clipped to close the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity. The external drainage tube led out the skin through the subcutaneous tunnel, and the dura was sutured.

    Procedure: Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach

  • Active comparator
    Trans-occipital keyhole approach

    After general anesthesia, the patient was placed in prone position with head frame fixed. According to the preoperative thin-layer CT scan, the long axis of hematoma was perpendicular to the ground, and the occipital puncture point was found along the extension line of the long axis of hematoma. Taking the puncture point as the center, a straight or arc incision parallel to the sagittal sinus was taken. The length of the incision was about 4cm, and the diameter of the bone window was about 2.5cm, Endoport and other hard channels were inserted to reach 2 / 3 of the long diameter of the hematoma along the direction parallel to the long axis of the hematoma. Under the neuroendoscope, the hematoma was aspirated or resected in blocks. During the operation, mini aneurysm clamp was used to clamp the responsible vessels, and hemostatic gauze was applied on the surface of the hematoma cavity. Silica gel external drainage tube was placed in the hematoma cavity.

    Procedure: The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery

Interventions

  • ProcedureThe Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery

    The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery

  • ProcedureEndoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach

    Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach

06

What researchers measure

Primary outcomes

  1. Clinical remission rate

    The evaluation criteria of complete remission: more than 85% of intracranial hematoma was cleared, mild brain edema, and the postoperative hospital stay was less than 2 weeks. The evaluation criteria of partial remission: the clearance rate of intracranial hematoma was 60% - 85%, the postoperative brain edema was obvious, and the postoperative hospital stay was less than 4 weeks.

    Time frame: 1 month postoperation

07

Study locations

1 site
  • Department of Neurosurgery, Shanghai Changzheng Hospital
    Shanghai, Shanghai 200003, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2022; primary completion for Dec 2024, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2021
First posted
Jul 12, 2021
StartEst.
Jan 1, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jun 30, 2025
Last update
Jul 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04957849
Collaborators
Beijing Tiantan Hospital, Huashan Hospital, Tianjin Medical University General Hospital, First Affiliated Hospital of Fujian Medical University, Peking Union Medical College Hospital, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Nanchang University, The General Hospital of Eastern Theater Command, First Affiliated Hospital of Harbin Medical University, Shengjing Hospital, ShuGuang Hospital, Qianfoshan Hospital
Responsible party
Hou Lijun (Professor, Shanghai Changzheng Hospital) — Principal investigator
First posted
Jul 12, 2021
Start date
Jan 1, 2022 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Jul 12, 2021

Study contacts

Lijun Hou, MD,PhD
Contact
houlijunsmmu@163.com
86 21 81885671
Liang Zhao, MD,PhD
Contact
15921509289@163.com
86 21 81885686
Lijun Hou, MD,PhD
principal investigator · Shanghai Changzheng Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion